Lucosky Brookman Advises Titan Partners Group in Belite Bio’s Strategic $15 Million Capital Raise

In a significant transaction for the biotechnology sector, Belite Bio, Inc (NASDAQ: BLTE) has secured $15 million through a registered direct offering, with potential for an additional $15 million through warrant exercises. The financing package, structured at market price, comprised 258,309 American Depositary Shares (ADSs) and accompanying warrants, each priced at $58.07.

The capital raise highlights growing market confidence in Belite Bio’s innovative pipeline targeting degenerative retinal diseases with substantial unmet medical needs. As a clinical-stage biopharmaceutical company, Belite Bio specializes in developing breakthrough therapeutics for conditions including Stargardt disease and Geographic Atrophy in advanced dry age-related macular degeneration.

The funding is earmarked to accelerate the company’s development initiatives through:

• Clinical program advancement
• Research and development expansion
• Working capital enhancement
• Strategic corporate initiatives

The transaction was executed under an effective shelf registration statement on Form F-3, with Titan Partners Group, a division of American Capital Partners, serving as the exclusive placement agent. Lucosky Brookman LLP acted as legal counsel to Titan Partners Group in the transaction.